Metastatic Breast Cancer research hub
15 indexed studies · 9 currently recruiting
- recruitingPHASE1, PHASE2
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
This study looks at a new drug, zongertinib, for different HER2+ cancers that have spread. Researchers want to find the best dose, alone and with other treatments, to see if it can shrink tumours.
United States · Belgium · China - active not recruitingPHASE1
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This study is testing two anti-cancer drugs, cabozantinib and atezolizumab, alone and together, for various advanced cancers. It aims to find a safe combination dose and see how well it works and any side effects.
United States · Australia · Belgium - recruitingPHASE2
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
This study looks at new treatments for advanced stomach or gullet cancer. It combines a new drug, ABBV-400, with existing chemotherapy and another new drug, Budigalimab. We want to find the safest and most effective dose and see how well it works.
United States · Belgium · Canada - active not recruitingPHASE2
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
This study looks at a new combination of experimental drugs, disitamab vedotin and tucatinib, for advanced breast or stomach cancers that have a specific marker called HER2. It aims to see how safe and effective this treatment is, and what side effects it might cause.
United States · Australia · Canada - active not recruitingPHASE2, PHASE3
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
This study, called ASPEN-06, looked into an experimental drug called Evorpacept for people in the UK with advanced stomach cancer (gastric cancer) that has a specific genetic marker (HER2-positive). It aimed to see if adding Evorpacept to standard treatments improved outcomes. The study has now been stopped due to strategic reasons.
United States · Australia · Belgium - recruitingPHASE1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
This study is for adults with advanced cancers in places like the lungs or stomach that are hard to treat or have spread. It's testing a new drug, PF-08046050, to see if it's safe and helps shrink these cancers, sometimes with other medicines.
United States · Canada · China - recruitingPHASE1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This study is testing a new drug called sigvotatug vedotin for people with several types of advanced cancer. Researchers want to see if it's safe, what side effects it causes, and if it can help treat cancer, sometimes in combination with other common cancer medicines.
United States · France · South Korea - recruitingPHASE1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
This study is looking at a new medicine called PF-08046876 for people with advanced cancers like bladder, lung, head & neck, oesophageal, or pancreatic cancer. It checks how safe the medicine is and how well it works. The medicine is given through a drip.
United States · Canada · Puerto Rico - active not recruitingPHASE3
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
This study looks at a new drug, trastuzumab deruxtecan, for people in the UK with HER2-positive stomach or food pipe cancer. It compares this drug to standard treatments for patients whose cancer has grown despite previous therapy. The aim is to see if the new drug works better and is safe.
Argentina · Belgium · Brazil - active not recruitingPHASE3
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
This study looks at a new drug, bemarituzumab, in combination with standard chemotherapy and nivolumab for advanced stomach or food pipe cancer. It aims to see if this new combination is safe and works better than current treatments, helping people with specific types of cancer live longer.
United States · Argentina · Australia - recruitingPHASE3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
This study looks at new drug combinations for stomach (gastric) or food pipe (GEJ) cancer that has a specific marker called HER2. It compares different treatment mixes to see which works best and is safest for advanced cancer.
United States · Argentina · Australia - recruitingPHASE3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
This study is testing new combinations of medicines (sonesitatug vedotin, rilvegostomig, and capecitabine) for advanced stomach, gastroesophageal junction, or oesophageal cancers. It aims to see how well they work and if they are safe for people whose cancer has a specific marker called Claudin18.2.
United States · Australia · Austria - recruitingPHASE3
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
This study looks at a new way to give a cancer drug called tislelizumab for advanced stomach cancer. We're comparing injections under the skin to drips into a vein, alongside usual chemotherapy. We want to see if the injection works just as well and is easier for patients.
United States · Argentina · Austria - recruitingPHASE2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
This study is testing a new oral medicine, APL-101, for people with advanced cancers. It focuses on lung cancer and other solid tumours where specific genetic changes linked to a protein called MET are found. Researchers want to see how well it works and if it's safe.
United States · Australia · Canada - active not recruitingPHASE2
Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness
This study compares a new drug, atezolizumab, plus standard chemotherapy (FLOT) against FLOT alone for stomach or food pipe cancer. It focuses on patients whose cancer shows certain immune markers, aiming to see if the new combination is safer and more effective before and after surgery.
Germany · Switzerland